Home > Neurology > ECTRIMS 2021 > Experimental Treatments > Evobrutinib reduces relapses and MRI lesion activity

Evobrutinib reduces relapses and MRI lesion activity

Presented By
Prof. Jens Kuhle (University Hospital Basel, Switzerland); Prof. Douglas Arnold (McGill University, Canada)
Conference
ECTRIMS 2021
Evobrutinib significantly reduced MRI activity and the number of MS patients with qualified relapses, regardless of baseline blood neurofilament light chain (NfL) levels. However, high levels of serum (s)NfL at baseline were highly predictive of increased relapse and MRI lesion activity [1]. Additionally, high dose evobrutinib reduced the volume of slowly expanding lesions (SELs) in patients with relapsing MS [2]. NfL is an established biomarker of neuro-axonal damage in MS. In a post-hoc analysis of a phase 2, randomised trial (NCT02975349), evobrutinib 75 mg twice daily significantly lowered blood NfL levels at weeks 12 and 24 [3]. In a new analysis, the interaction of sNfL levels and the effects of a Bruton's tyrosine kinase (BTK) inhibitor in MS patients was evaluated for the first time. Prof. Jens Kuhle (University Hospital Ba...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on